Bacterial glycosidases in pathogenesis and glycoengineering

Future Microbiology

Volumn 9, Issue 9, 2014, Pages 1039-1051

  Sjögren, Jonathan ^a   Collin, Mattias ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

bacterial pathogenesis; glycoengineering; glycosidases; glycosylation; IgG

Indexed keywords

BACTERIAL ENZYME; GLYCOSIDASE; IMMUNOGLOBULIN G; BACTERIAL PROTEIN; POLYSACCHARIDE;

BACTERIAL COLONIZATION; ENZYME ACTIVITY; GLYCOBIOLOGY; GLYCOENGINEERING; HOST PATHOGEN INTERACTION; IMMUNE ADHERENCE; IMMUNOMODULATION; INFECTION; NONHUMAN; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN ENGINEERING; PROTEIN GLYCOSYLATION; PROTEIN MODIFICATION; REVIEW; BACTERIUM; BACTERIUM ADHERENCE; ENZYMOLOGY; GLYCOSYLATION; METABOLISM; PROTEIN PROCESSING;

BACTERIA (MICROORGANISMS);

BACTERIA; BACTERIAL ADHESION; BACTERIAL PROTEINS; GLYCOSIDE HYDROLASES; GLYCOSYLATION; IMMUNOGLOBULIN G; POLYSACCHARIDES; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 84908148687     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.14.71     Document Type: Review

References (93)

1. Rudd P, Elliott T, Cresswell P, Wilson I, Dwek R. Glycosylation and the immune system. Science 291(5512), 2370-2376 (2001).
2. Szymanski CM, Wren BW. Protein glycosylation in bacterial mucosal pathogens. Nat. Rev. Microbiol. 3(3), 225-237 (2005).
3. Krapp S, Mimura Y, Jefferis R, Huber R, Sondermann P. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J. Mol. Biol. 325(5), 979-989 (2003).
4. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat. Rev. Drug Discov. 8(3), 226-234 (2009).
5. Anthony RM, Ravetch JV. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J. Clin. Immunol. 30(Suppl. 1), S9-S14 (2010).
6. Ackerman ME, Crispin M, Yu X, et al. Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J. Clin. Invest. 123(5), 2183-2192 (2013).
7. Bojarová P, Kren V. Glycosidases: a key to tailored carbohydrates. Trends Biotechnol. 27(4), 199-209 (2009).
8. Carbohydrate-Active Enzymes (CAZy) database. www.cazy.org
9. Cunningham M. Pathogenesis of group A streptococcal infections. Clin. Microbiol. Rev. 13(3), 470-511 (2000).
10. Carapetis J, Steer A, Mulholland E, Weber M. The global burden of group A streptococcal diseases. Lancet Infect. Dis. 5(11), 685-694 (2005).
11. Nizet V. Understanding how leading bacterial pathogens subvert innate immunity to reveal novel therapeutic targets. J. Allergy Clin. Immunol. 120(1), 13-22 (2007).
12. Walker MJ, Barnett TC, McArthur JD, et al. Disease manifestations and pathogenic mechanisms of group A Streptococcus. Clin. Microbiol. Rev. 27(2), 264-301 (2014).
13. Collin M, Olsén A. EndoS, a novel secreted protein from Streptococcus pyogenes with endoglycosidase activity on human IgG. EMBO J. 20(12), 3046-3055 (2001).
14. Collin M, Olsén A. Effect of SpeB and EndoS from Streptococcus pyogenes on human immunoglobulins. Infect. Immun. 69(11), 7187-7189 (2001).
15. Collin M, Svensson M, Sjöholm A, Jensenius J, Sjöbring U, Olsén A. EndoS and SpeB from Streptococcus pyogenes inhibit immunoglobulin-mediated opsonophagocytosis. Infect. Immun. 70(12), 6646 (2002).
16. Allhorn M, Olin AI, Nimmerjahn F, Collin M. Human IgG/Fc?R interactions are modulated by streptococcal IgG glycan hydrolysis. PLoS ONE 3(1), e1413 (2008).
17. Dixon EV, Claridge JK, Harvey DJ, et al. Fragments of bacterial endoglycosidase S and immunoglobulin G reveal subdomains of each that contribute to deglycosylation. J. Biol. Chem. 289(20), 13876-13889 (2014).
18. Sjögren J, Okumura CY, Collin M, Nizet V, Hollands A. Study of the IgG endoglycosidase EndoS in group A streptococcal phagocyte resistance and virulence. BMC Microbiol. 11(1), 120 (2011).
19. Sjögren J, Struwe WB, Cosgrave EFJ, et al. EndoS2 is a unique and conserved enzyme of serotype M49 group A Streptococcus that hydrolyses N-linked glycans on IgG and a1-Acid glycoprotein. Biochem. J. 455(1), 107-118 (2013).
20. Flock M, Frykberg L, Sköld M, Guss B, Flock J-I. Antiphagocytic function of an IgG glycosyl hydrolase from Streptococcus equi subsp. equi and its use as a vaccine component. Infect. Immun. 80(8), 2914-2919 (2012).
21. Collin M, Fischetti VA. A novel secreted endoglycosidase from Enterococcus faecalis with activity on human immunoglobulin G and ribonuclease B. J. Biol. Chem. 279(21), 22558-22570 (2004).
22. Garbe J, Sjögren J, Cosgrave EFJ, et al. EndoE from Enterococcus faecalis hydrolyzes the glycans of the biofilm inhibiting protein lactoferrin and mediates growth. PLoS ONE 9(3), e91035 (2014).
23. Bøhle LA, Mathiesen G, Vaaje Kolstad G, Eijsink VGH. An endo-β-N-Acetylglucosaminidase from Enterococcus faecalis V583 responsible for the hydrolysis of high-mannose and hybrid-Type N-linked glycans. FEMS Microbiol. Lett. 325(2), 123-129 (2011).
24. Chaudhuri S, Bruno JC, Alonzo F III, Xayarath B, Cianciotto NP, Freitag NE. Contribution of chitinases to Listeria monocytogenes pathogenesis. Appl. Environ. Microb. 76(21), 7302-7305 (2010).
25. Chaudhuri S, Gantner BN, Ye RD, Cianciotto NP, Freitag NE. The Listeria monocytogenes ChiA chitinase enhances virulence through suppression of host innate immunity. mBio 4(2), e00617-12 (2013).
26. Lewis WG, Robinson LS, Perry J, et al. Hydrolysis of secreted sialoglycoprotein immunoglobulin A (IgA) in ex vivo and biochemical models of bacterial vaginosis. J. Biol. Chem. 287(3), 2079-2089 (2012).
27. Bogaert D, de Groot R, Hermans P. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect. Dis. 4(3), 144-154 (2004).
28. King SJ. Pneumococcal modification of host sugars: a major contributor to colonization of the human airway?. Mol. Oral Microbiol. 25(1), 15-24 (2010).
29. Clarke VA, Platt N, Butters TD. Cloning and expression of the β-N-Acetylglucosaminidase gene from Streptococcus pneumoniae. J. Biol. Chem. 270(15), 8805-8814 (1995).
30. Zdhner D, Hakenbeck R. The Streptococcus pneumoniae β-galactosidase is a surface protein. J. Bacteriol. 182(20), 5919-5921 (2000).
31. Cámara M, Boulnois GJ, Andrew PW, Mitchell TJ. A neuraminidase from Streptococcus pneumoniae has the features of a surface protein. Infect. Immun. 62(9), 3688-3695 (1994).
32. Pluvinage B, Higgins MA, Abbott DW, et al. Inhibition of the pneumococcal virulence factor StrH and molecular insights into N-glycan recognition and hydrolysis. Structure 19(11), 1603-1614 (2011).
33. King SJ, Hippe KR, Weiser JN. Deglycosylation of human glycoconjugates by the sequential activities of exoglycosidases expressed by Streptococcus pneumoniae. Mol. Microbiol. 59(3), 961-974 (2006).
34. King SJ, Hippe KR, Gould JM, et al. Phase variable desialylation of host proteins that bind to Streptococcus pneumoniae in vivo and protect the airway. Mol. Microbiol. 54(1), 159-171 (2004).
35. Uchiyama S, Carlin AF, Khosravi A, et al. The surface-Anchored NanA protein promotes pneumococcal brain endothelial cell invasion. J. Exp. Med. 206(9), 1845-1852 (2009).
36. Chang YC, Uchiyama S, Varki A, Nizet V. Leukocyte inflammatory responses provoked by pneumococcal sialidase. MBio 3(1), e00220-11 (2011).
37. Grewal PK, Uchiyama S, Ditto D, et al. The Ashwell receptor mitigates the lethal coagulopathy of sepsis. Nat. Med. 14(6), 648-655 (2008).
38. Grewal PK, Aziz PV, Uchiyama S, et al. Inducing host protection in pneumococcal sepsis by preactivation of the Ashwell-Morell receptor. Proc. Natl Acad. Sci. USA 110(50), 20218-20223 (2013).
39. Bhavanandan VP, Umemoto J, Davidson EA. Characterization of an endo-a-N-Acetyl galactosaminidase from Diplococcus pneumoniae. Biochem. Biophys. Res. Commun. 70(3), 738-745 (1976).
40. Caines MEC, Zhu H, Vuckovic M, et al. The structural basis for T-Antigen hydrolysis by Streptococcus pneumoniae: a target for structure-based vaccine design. J. Biol. Chem. 283(46), 31279-31283 (2008).
41. Marion C, Limoli DH, Bobulsky GS, Abraham JL, Burnaugh AM, King SJ. Identification of a pneumococcal glycosidase that modifies O-linked glycans. Infect. Immun. 77(4), 1389-1396 (2009).
42. Pastoriza Gallego M, Hulen C. Influence of sialic acid and bacterial sialidase on Differential adhesion of Pseudomonas aeruginosa to epithelial cells. Colloids Surf. B Biointerfaces 52(2), 154-156 (2006).
43. Martino AT, Mueller C, Braag S, et al. N-glycosylation augmentation of the cystic fibrosis epithelium improves Pseudomonas aeruginosa clearance. Am. J. Respir. Cell Mol. Biol. 44(6), 824-830 (2011).
44. Rohmer L, Hocquet D, Miller SI. Are pathogenic bacteria just looking for food?. Metabolism and microbial pathogenesis. Trends Microbiol. 19(7), 341-348 (2011).
45. Shelburne SA, Davenport MT, Keith DB, Musser JM. The role of complex carbohydrate catabolism in the pathogenesis of invasive streptococci. Trends Microbiol. 16(7), 318-325 (2008).
46. Shelburne SA, Keith D, Horstmann N, et al. A direct link between carbohydrate utilization and virulence in the major human pathogen group A Streptococcus. Proc. Natl Acad. Sci. USA 105(5), 1698-1703 (2008).
47. Garbe J, Collin M. Bacterial hydrolysis of host glycoproteins - powerful protein modification and efficient nutrient acquisition. J. Innate Immun. 4(2), 121-131 (2012).
48. Renzi F, Manfredi P, Mally M, Moes S, Jenö P, Cornelis G. The N-glycan glycoprotein Deglycosylation complex (Gpd) from Capnocytophaga canimorsus deglycosylates human IgG. PLoS Pathog. 7(6), 17 (2011).
49. Byers HL, Tarelli E, Homer KA, Beighton D. Sequential deglycosylation and utilization of the N-linked, complex-Type glycans of human a1-Acid glycoprotein mediates growth of Streptococcus oralis. Glycobiology 9(5), 469-479 (1999).
50. Kurniyati K, Zhang W, Zhang K, Li C. A surface-exposed neuraminidase affects complement resistance and virulence of the oral spirochaete Treponema denticola. Mol. Microbiol. 89(5), 842-856 (2013).
51. Garrido D, Nwosu C, Ruiz-Moyano S, et al. Endo-β-N-Acetylglucosaminidases from infant gut-Associated bifidobacteria release complex N-glycans from human milk glycoproteins. Mol. Cell. Proteomics 11(9), 775-785 (2012).
52. Dallas DC, Sela D, Underwood MA, German JB, Lebrilla C. Protein-linked glycan Degradation in infants fed human milk. J. Glycomics Lipidomics (Suppl. 1), 002 (2012).
53. Pultz NJ, Hoskins LC, Donskey CJ. Vancomycin-resistant enterococci may obtain nutritional support by scavenging carbohydrate fragments generated during mucin Degradation by the anaerobic microbiota of the colon. Microb. Drug Resist. 12(1), 63-67 (2006).
54. Ng KM, Ferreyra JA, Higginbottom SK, et al. Microbiota-liberated host sugars facilitate post-Antibiotic expansion of enteric pathogens. Nature 502(7469), 96-99 (2014).
55. Png CW, Lindén SK, Gilshenan KS, et al. Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. Am. J. Gastroenterol. 105(11), 2420-2428 (2010).
56. Tradtrantip L, Ratelade J, Zhang H, Verkman AS. Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti-Aquaporin-4 immunoglobulin G into therapeutic antibody. Ann. Neurol. 73(1), 77-85 (2012).
57. Baruah K, Bowden TA, Krishna BA, Dwek RA, Crispin M, Scanlan CN. Selective deactivation of serum IgG: a general strategy for the enhancement of monoclonal antibody receptor interactions. J. Mol. Biol. 420(1-2), 1-7 (2012).
58. Huang W, Giddens J, Fan S-Q, Toonstra C, Wang L-X. Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions. J. Am. Chem. Soc. 134(29), 12308-12318 (2012).
59. Smith EL, Giddens JP, Iavarone AT, Godula K, Wang L-X, Bertozzi CR. Chemoenzymatic Fc glycosylation via engineered aldehyde tags. Bioconjug. Chem. 25(4), 788-795 (2014).
60. Allhorn M, Briceno JG, Baudino L, et al. The IgG-specific endoglycosidase EndoS inhibits both cellular and complement-mediated autoimmune hemolysis. Blood 115(24), 5080-5088 (2010).
61. Benkchoucha M, Molnarfi N, Santiago-Raber M-L, et al. IgG glycan hydrolysis by EndoS inhibits experimental autoimmune encephalomyelitis. J. Neuroinflammation 9(1), 209 (2012).
62. Hirose M, Vafia K, Kalies K, et al. Enzymatic autoantibody glycan hydrolysis alleviates autoimmunity against type VII collagen. J. Autoimmun. 39(4), 304-314 (2012).
63. Lood C, Allhorn M, Lood R, et al. IgG glycan hydrolysis by endoglycosidase S diminishes the proinflammatory properties of immune complexes from patients with systemic lupus erythematosus: a possible new treatment?. Arthritis Rheum. 64(8), 2698-2706 (2012).
64. Nandakumar KS, Collin M, Olsén A, et al. Endoglycosidase treatment abrogates IgG arthritogenicity: importance of IgG glycosylation in arthritis. Eur. J. Immunol. 37(10), 2973-2982 (2007).
65. Yang R, Otten MA, Hellmark T, et al. Successful treatment of experimental glomerulonephritis with IdeS and EndoS, IgG-degrading streptococcal enzymes. Nephrol. Dial. Transplant. 25(8), 2479-2486 (2010).
66. van Timmeren MM, van Der Veen BS, Stegeman CA, et al. IgG glycan hydrolysis attenuates ANCA-mediated glomerulonephritis. J. Am. Soc. Nephrol. 21(7), 1103-1114 (2010).
67. Collin M. EndoS, a 'drug from a bug' as a novel treatment for autoimmunity of the blood. ISBT Sci. Series 7(1), 142-145 (2012).
68. Trastoy B, Lomino JV, Pierce BG, et al. Crystal structure of Streptococcus pyogenes EndoS, an immunomodulatory endoglycosidase specific for human IgG antibodies. Proc. Natl Acad. Sci. USA 111(18), 6714-6719 (2014).
69. Lomino JV, Naegeli A, Orwenyo J, Amin MN, Aebi M, Wang L-X. A two-step enzymatic glycosylation of polypeptides with complex N-glycans. Bioorg. Med. Chem. 21(8), 2262-2270 (2013).
70. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7(9), 715-725 (2007).
71. Radaev S, Sun PD. Recognition of IgG by Fcgamma receptor. The role of Fc glycosylation and the binding of peptide inhibitors. J. Biol. Chem. 276(19), 16478-16483 (2001).
72. Bakchoul T, Greinacher A, Sachs UJ, et al. Inhibition of HPA-1a alloantibody-mediated platelet destruction by a deglycosylated anti-HPA-1a monoclonal antibody in mice: toward targeted treatment of fetal-Alloimmune thrombocytopenia. Blood 122(3), 321-327 (2013).
73. Muramatsu T. Demonstration of an endo-glycosidase acting on a glycoprotein. J. Biol. Chem. 246(17), 5535-5537 (1971).
74. Fan S-Q, Huang W, Wang L-X. Remarkable transglycosylation activity of glycosynthase mutants of endo-D, an endo-β-N-Acetylglucosaminidase from Streptococcus pneumoniae. J. Biol. Chem. 287(14), 11272-11281 (2012).
75. Goetze AM, Liu YD, Zhang Z, et al. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology. 21(7), 949-959 (2011).
76. Abbott DW, Boraston A. Structural analysis of a putative family 32 carbohydrate-binding module from the Streptococcus pneumoniae enzyme EndoD. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 67(4), 429-433 (2011).
77. Elder JH, Alexander S. Endo-β-N-Acetylglucosaminidase F: endoglycosidase from Flavobacterium meningosepticum that cleaves both high-mannose and complex glycoproteins. Proc. Natl Acad. Sci. USA 79(15), 4540-4544 (1982).
78. Plummer TH, Elder JH, Alexander S, Phelan AW, Tarentino AL. Demonstration of peptide:N-glycosidase F activity in endo-β-N-Acetylglucosaminidase F preparations. J. Biol. Chem. 259(17), 10700-10704 (1984).
79. Ruhaak LR, Zauner G, Huhn C, Bruggink C, Deelder AM, Wuhrer M. Glycan labeling strategies and their use in identification and quantification. Anal. Bioanal. Chem. 397(8), 3457-3481 (2010).
80. Tharmalingam T, Adamczyk B, Doherty MA, Royle L, Rudd PM. Strategies for the profiling, characterisation and detailed structural analysis of N-linked oligosaccharides. Glycoconj. J. 30(2), 137-146 (2012).
81. Pučić M, Kneževicć A, Vidic J, et al. High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations. Mol. Cell Proteom. 10(10), M111.010090 (2011).
82. Ratnamani MS, Rao R. Elizabethkingia meningoseptica: emerging nosocomial pathogen in bedside hemodialysis patients. Indian J. Crit. Care Med. 17(5), 304-307 (2013).
83. Chang Y-C, Lo H-H, Hsieh H-Y, Chang S-M. Identification and epidemiological relatedness of clinical Elizabethkingia meningoseptica isolates from central Taiwan. J. Microbiol. Immunol. Infect. 47(4), 318-323 (2013).
84. Robbins PW, Trimble RB, Wirth DF, et al. Primary structure of the Streptomyces enzyme endo-beta-N-Acetylglucosaminidase H. J. Biol. Chem. 259(12), 7577-7583 (1984).
85. Breidenbach MA, Gallagher JEG, King DS, Smart BP, Wu P, Bertozzi CR. Targeted metabolic labeling of yeast N-glycans with unnatural sugars. Proc. Natl Acad. Sci. USA 107(9), 3988-3993 (2010).
86. Wada Y, Dell A, Haslam SM, et al. Comparison of methods for profiling O-glycosylation: Human Proteome Organisation Human Disease Glycomics/Proteome Initiative multi-institutional study of IgA1. Mol. Cell. Proteomics 9(4), 719-727 (2010).
87. Goda HM, Ushigusa K, Ito H, Okino N, Narimatsu H, Ito M. Molecular cloning, expression, and characterization of a novel endo-A-N-Acetylgalactosaminidase from Enterococcus faecalis. Biochem. Biophys. Res. Commun. 375(4), 541-546 (2008).
88. Koutsioulis D, Landry D, Guthrie EP. Novel endo-a-N-Acetylgalactosaminidases with broader substrate specificity. Glycobiology 18(10), 799-805 (2008).
89. Fujita K, Oura F, Nagamine N, et al. Identification and molecular cloning of a novel glycoside hydrolase family of core 1 type O-glycan-specific endo-a-N-Acetylgalactosaminidase from Bifidobacterium longum. J. Biol. Chem. 280(45), 37415-37422 (2005).
90. Fan JQ, Kadowaki S, Yamamoto K, Kumagai H, Tochikura T. Purification and characterization of endo-a-N-Acetyl-galactosaminidase from Alcaligenes sp. Agric. Biol. Chem. 52(7), 1715-1723 (1988).
91. Yamamoto K, Fan J-Q, Kadowaki S, Kumagai H, Tochikura T. Isolation of endo-a-N-Acetylgalactosaminidase from an aerobic bacterium. Agric. Biol. Chem. 51(11), 3169-3171 (1987).
92. Ashida H, Yamamoto K, Murata T, Usui T, Kumagai H. Characterization of endo-a-N-Acetylgalactosaminidase from Bacillus sp. and syntheses of neo-oligosaccharides using its transglycosylation activity. Arch. Biochem. Biophys. 373(2), 394-400 (2000).
93. Iwase H, Ishii I, Ishihara K, Tanaka Y, Omura S, Hotta K. Release of oligosaccharides possessing reducing-end N-Acetylgalactosamine from mucus glycoprotein in Streptomyces sp. OH-11242 culture medium through action of endo-Type glycosidase. Biochem. Biophys. Res. Commun. 151(1), 422-428 (1988).